Article: Medarex Announces That Bay City Capital Offers to Purchase Rights For Up to $44 Million in Medarex Stock

ANNANDALE, N.J., June 11 /PRNewswire/ -- Medarex, Inc. (Nasdaq: MEDX) a biopharmaceutical company specializing in antibody-based therapeutics, announced today that BCC Acquisition I LLC ("BCC") a limited liability company formed between The Bay City Capital Fund I, L.P., an affiliate of Bay City Capital LLC, and various Pritzker family business interests has made an offer to purchase rights to receive shares of Medarex common stock totaling approximately $44.4 million.

The rights in question are held by former shareholders of GenPharm International, Inc. as a result of Medarex's acquisition of GenPharm in October 1997 for a total of up to $62.7 million in stock, ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!